Our focus is deeply rooted
in severe lung disease

Webcast, Nov 4 - Oral presentation by Toby Maher on the interim results of the IPF trial

View event

Webcast, Nov 4 - Presentation from event

View presentation

Financial reports

Interim report, Q3 Interim report, Q2 Interim report, Q1 Read more

Latest press releases

December 30, 2022 Increase of number of shares and votes in Vicore Pharma
December 8, 2022 Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million
Read more Subscribe

Upcoming events

Read more

About us

Vicore is a clinical-stage pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Fibrotic lung disease

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis and is a severe and devastating disease with no known cause. It is characterized by a shrinking of the lungs due to the irreversible formation of fibrosis (i.e. scar tissue) causing stiffness, an irreversible loss of lung function and difficulty in breathing.

Our Vision

Vicore’s vision is to remove the pain and suffering caused by severe lung disease. As a company, we pride ourselves on our collaborative approach to science and are committed to working closely with the patient community, scientific experts and clinicians to find innovative solutions that meet their needs.